Autopsy report · NCT02376699
Safety Study of SEA-CD40 in Cancer Patients
Cause of deathFunding or business
“Study closed due to portfolio prioritization”
Life of this trial
- Ran for about 8 years 2 months before it stopped.
- 159 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Seagen Inc.
- Sponsor type
- Industry
- Conditions
- Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular
- Interventions
- Intravenous (IV) SEA-CD40; Pembrolizumab; Subcutaneous (SC) SEA-CD40; Gemcitabine; Nab-paclitaxel
- Participants
- 159
- Sites
- 19
- Countries
- United States
Trials that died the same way
- A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
“termination due to portfolio prioritization” - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
“Portfolio re-prioritization” - Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
“Project discontinued to prioritize other key programs in portfolio” - Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
“study stopped due to company strategic prioritization” - HPV16 E6 TCR T Cells for Cervical Carcinoma
“Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.